{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:14:34Z","timestamp":1790853274393,"version":"4.1.0"},"reference-count":36,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: c-Met (also known as MET) protein is encoded by the MET proto-oncogene. In non-small cell lung cancer (NSCLC), c-Met protein overexpression (OE) drives tumorigenesis and is a therapeutic target, given recent US Food and Drug Administration approval of telisotuzumab vedotin-tllv. This retrospective analysis of tumor samples and clinical data from real-world patients with non-squamous NSCLC characterized the prevalence of c-Met protein OE, its association with messenger ribonucleic acid (mRNA) expression, MET gene amplification, programmed-death ligand 1 (PD-L1) expression, and its impact on prognosis.\nPatients and methods: A patient cohort was selected for manual abstraction of clinical data from electronic health records. Patients were selected based on the availability of sufficient remnant tissue for biomarker analyses, including c-Met immunohistochemistry (IHC). Comparative assessments were conducted for c-Met protein expression by IHC, MET gene amplification, mRNA expression, and PD-L1 expression levels by IHC.\nResults: In total, 305 and 84 patients were included in the biomarker prevalence and outcome analyses, respectively. Overall, c-Met protein OE was detected in 25% of tissue samples. Of the 212 samples with fluorescence in situ hybridization data, MET amplification was seen in 9%. Concordance of c-Met protein OE with MET mRNA levels was observed with area under the concentration-time curve values of 0.738 and 0.736 in MET OE or MET high OE, respectively, using Receiver Operating Characteristic analysis. c-Met protein OE was associated with poor prognosis (unadjusted hazard ratio for death of 2.04).\nInterpretation: These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.44344","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:03:22Z","timestamp":1763532202000},"page":"1544-1553","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":false,"given":"Jair","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona H.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yookyung Christy","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Baijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Liede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Vasilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Roberts-Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ratajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"133237","doi-asserted-by":"crossref","unstructured":"Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012;30:3287\u201396.","DOI":"10.1200\/JCO.2011.40.3774"},{"key":"133238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3774"},{"key":"133239","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8924(03)00104-1"},{"key":"133240","doi-asserted-by":"crossref","unstructured":"Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:S7\u201319.","DOI":"10.1177\/1758834011422556"},{"key":"133241","doi-asserted-by":"publisher","DOI":"10.1177\/1758834011422556"},{"key":"133242","doi-asserted-by":"crossref","unstructured":"Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metast Rev. 2008;27:85\u201394.","DOI":"10.1007\/s10555-007-9107-6"},{"key":"133243","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9107-6"},{"key":"133244","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2135113100"},{"key":"133245","doi-asserted-by":"crossref","unstructured":"Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309\u201325.","DOI":"10.1023\/A:1023768811842"},{"key":"133246","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023768811842"},{"key":"133247","doi-asserted-by":"crossref","unstructured":"Wang R, Kobayashi R, Bishop JM. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci U S A. 1996;93:8425\u201330.","DOI":"10.1073\/pnas.93.16.8425"},{"key":"133248","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8425"},{"key":"133249","doi-asserted-by":"crossref","unstructured":"Qiao H, Hung W, Tremblay E, Wojcik J, Gui J, Ho J, et al. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem. 2002;86:665\u201377.","DOI":"10.1002\/jcb.10239"},{"key":"133250","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10239"},{"key":"133251","unstructured":"Ansell PJ, Baijal S, Liede A, Raskin L, Xiaoyu X, Vasilopoulos A, et al. Prevalence and characterization of c-MET\u2013overexpressing non-small cell lung cancer (NSCLC) across clinical trial samples and real-world patient cohorts from the City of Hope National Medical Center. In: Cancer Research UK (CRUK) \u2013 Lung Cancer Conference; Manchester; November 15\u201317, 2022."},{"key":"133252","doi-asserted-by":"crossref","unstructured":"Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR, et al. Overexpression and activation of hepatocyte growth factor\/scatter factor in human non-small-cell lung carcinomas. Br J Cancer. 1996;74:1862\u20138.","DOI":"10.1038\/bjc.1996.646"},{"key":"133253","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.646"},{"key":"133254","doi-asserted-by":"crossref","unstructured":"Recondo G, Che C, J\u00e4nne PA, Awad MM. Targeting MET dysregulation in cancer. Cancer Discov. 2020;10:922\u201334.","DOI":"10.1158\/2159-8290.CD-19-1446"},{"key":"133255","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1446"},{"key":"133256","doi-asserted-by":"crossref","unstructured":"Motwani M, Panchabhai S, Bar J, Girard N, Bradbury P, Lu S, et al. Prevalence of c-Met overexpression (c-Met+) and impact of prior lines of treatment on c-Met protein expression in NSCLC. J Thorac Oncol. 2021;16:S1169\u201370. Abstract P60.12.","DOI":"10.1016\/j.jtho.2021.08.633"},{"key":"133257","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.633"},{"key":"133258","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression [press release]. May 14, 2025. [cited 2025 Jun 7]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression"},{"key":"133259","doi-asserted-by":"crossref","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024;42:3000\u201311.","DOI":"10.1200\/JCO.24.00720"},{"key":"133260","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720"},{"key":"133261","doi-asserted-by":"crossref","unstructured":"Spitaleri G, Aliaga PT, Attili I, Del Signore E, Corvaja C, Corti C, et al. MET in non-small-cell lung cancer (NSCLC): cross \u2018a long and winding road\u2019 looking for a target. Cancers (Basel). 2023;15:4779.","DOI":"10.3390\/cancers15194779"},{"key":"133262","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194779"},{"key":"133263","doi-asserted-by":"crossref","unstructured":"Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF\/c-Met axis. Onco Targets Ther. 2020;13:2491\u2013510.","DOI":"10.2147\/OTT.S231257"},{"key":"133264","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S231257"},{"key":"133265","doi-asserted-by":"crossref","unstructured":"Ding C, Qiu Y, Zhang J, Wei W, Gao H, Yuan Y, et al. Clinicopathological characteristics of non-small cell lung cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification. BMC Pulm Med. 2023;23:240.","DOI":"10.1186\/s12890-023-02482-9"},{"key":"133266","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02482-9"},{"key":"133267","doi-asserted-by":"crossref","unstructured":"Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9:e99399.","DOI":"10.1371\/journal.pone.0099399"},{"key":"133268","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099399"},{"key":"133269","doi-asserted-by":"crossref","unstructured":"Ma G, Deng Y, Chen W, Liu Z, Ai C, Li X, et al. The prognostic role of MET protein expression among surgically resected non-small cell lung cancer patients: a meta-analysis. Front Oncol. 2019;9:1441.","DOI":"10.3389\/fonc.2019.01441"},{"key":"133270","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01441"},{"key":"133271","doi-asserted-by":"crossref","unstructured":"Camidge DR, Raimbourg J, Lee YG, de Miguel MJ, Hollebecque A, Kim TM, et al. Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase 1 study. J Clin Oncol. 2025;43(16_suppl):8512.","DOI":"10.1200\/JCO.2025.43.16_suppl.8512"},{"key":"133272","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8512"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44344\/52051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44344\/52110","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44344\/52111","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/44344\/52051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T10:34:41Z","timestamp":1764844481000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/44344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":36,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.44344","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}